Radiotherapy accelerators have undergone continuous technological developments. We investigated the differences between Radixact (TM) and VMAT treatment plans. Sixty patients were included in this study. Dosimetric comparison between the Radixact (TM) and VMAT plans was performed for six cancer sites: whole-brain, head and neck, lymphoma, lung, prostate, and rectum. The VMAT plans were generated with two Elekta linear accelerators (Synergy((R)) and Versa HD (TM)). The planning target volume (PTV) coverage, organs-at-risk dose constraints, and four dosimetric indexes were considered. The deliverability of the plans was assessed using quality assurance (gamma index evaluation) measurements; clinical judgment was included in the assessment. The mean AAPM TG218 (3%-2 mm, global normalization) gamma index values were 99.4%, 97.8%, and 96.6% for Radixact (TM), Versa HD (TM), and Synergy (R), respectively. Radixact (TM) performed better than Versa HD (TM) in terms of dosimetric indexes, hippocampi D-100%, spinal cord D-max, rectum V-38.4 Gy, bladder V-30 Gy, and V-40 Gy. Versa HD (TM) saved more of the (lungs-PTV) V-5 Gy and (lungs-PTV) D-mean, heart D-mean, breasts V-4 Gy, and bowel V-45 Gy. Regarding Synergy((R)), the head and neck Radixact (TM) plan saved more of the parotid gland, oral cavity, and supraglottic larynx. From a clinical point of view, for the head and neck, prostate, and rectal sites, the Radixact (TM) and Versa HD (TM) plans were similar; Radixact (TM) plans were preferable for the head and neck and rectum to Synergy((R)) plans. The quality of linac plans has improved, and differences with tomotherapy have decreased. However, tomotherapy continues to be an essential add-on in multi-machine departments.

Helical tomotherapy and two types of volumetric modulated arc therapy: dosimetric and clinical comparison for several cancer sites

Sardo, Anna;Badellino, Serena;Mantovani, Cristina;Levis, Mario;Fiandra, Christian;Guarneri, Alessia;Arcadipane, Francesca;Richetto, Veronica;Ricardi, Umberto;
2023-01-01

Abstract

Radiotherapy accelerators have undergone continuous technological developments. We investigated the differences between Radixact (TM) and VMAT treatment plans. Sixty patients were included in this study. Dosimetric comparison between the Radixact (TM) and VMAT plans was performed for six cancer sites: whole-brain, head and neck, lymphoma, lung, prostate, and rectum. The VMAT plans were generated with two Elekta linear accelerators (Synergy((R)) and Versa HD (TM)). The planning target volume (PTV) coverage, organs-at-risk dose constraints, and four dosimetric indexes were considered. The deliverability of the plans was assessed using quality assurance (gamma index evaluation) measurements; clinical judgment was included in the assessment. The mean AAPM TG218 (3%-2 mm, global normalization) gamma index values were 99.4%, 97.8%, and 96.6% for Radixact (TM), Versa HD (TM), and Synergy (R), respectively. Radixact (TM) performed better than Versa HD (TM) in terms of dosimetric indexes, hippocampi D-100%, spinal cord D-max, rectum V-38.4 Gy, bladder V-30 Gy, and V-40 Gy. Versa HD (TM) saved more of the (lungs-PTV) V-5 Gy and (lungs-PTV) D-mean, heart D-mean, breasts V-4 Gy, and bowel V-45 Gy. Regarding Synergy((R)), the head and neck Radixact (TM) plan saved more of the parotid gland, oral cavity, and supraglottic larynx. From a clinical point of view, for the head and neck, prostate, and rectal sites, the Radixact (TM) and Versa HD (TM) plans were similar; Radixact (TM) plans were preferable for the head and neck and rectum to Synergy((R)) plans. The quality of linac plans has improved, and differences with tomotherapy have decreased. However, tomotherapy continues to be an essential add-on in multi-machine departments.
2023
16
272
283
Dose comparison; Linac; Radixact™; Tomotherapy; VMAT
Gallio, Elena; Sardo, Anna; Badellino, Serena; Mantovani, Cristina; Levis, Mario; Fiandra, Christian; Guarneri, Alessia; Arcadipane, Francesca; Richet...espandi
File in questo prodotto:
File Dimensione Formato  
Helical Tomotherapy.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.6 MB
Formato Adobe PDF
1.6 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1904526
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact